Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Poly MedicureNSE:POLYMED +2.09%99 PS Ratio is 9.16 as of Aug. 01, 2026, which is 4% above its 10-year median of 8.84. GuruFocus rates NSE:POLYMED with a GF Score™ of 99/100 and a GF Value™ of ₹2,368.71 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Poly Medicure ranks worse than 82.94% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Poly Medicure's share price is ₹1702.00.
Poly Medicure's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹185.83. Hence, Poly Medicure's PS Ratio for today is 9.16.
The historical rank and industry rank for Poly Medicure's PS Ratio or its related term are showing as below:
NSE:POLYMED'
s PS Ratio Range Over the Past 10 Years
Min: 2.43 Med: 8.84 Max: 20.14
Current: 9.24
During the past 13 years, Poly Medicure's highest PS Ratio was 20.14. The lowest was 2.43. And the median was 8.84.
NSE:POLYMED's PS Ratio is ranked worse than 82.94% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 2.91
vs NSE:POLYMED: 9.24
Poly Medicure Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Poly Medicure was 6.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 17.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 15.30% per year.
During the past 13 years, Poly Medicure's highest 3-Year average Revenue per Share Growth Rate was 27.00% per year. The lowest was 9.70% per year. And the median was 16.70% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Poly Medicure PS Ratio Related Terms
Poly Medicure PS Ratio Historical Data
* Premium members only.
The historical data trend for Poly Medicure's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:POLYMED vs ISRG, BDX, MDLN: PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Poly Medicure's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poly Medicure PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Poly Medicure's PS Ratio distribution charts can be found below:
* The bar in red indicates where Poly Medicure's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Poly Medicure's Share Price of today is ₹1702.00. Poly Medicure's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹185.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Poly Medicure (NSE:POLYMED) has a PS Ratio of 9.16 as of Aug. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Poly Medicure and its competitors. This is near median its historical median of 8.84. Over the past decade, Poly Medicure's PS Ratio has ranged from 2.43 to 20.14. According to the industry distribution chart, Poly Medicure ranks #666 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 82.9%.
Is Poly Medicure's PS Ratio too high?
Poly Medicure's current PS Ratio of 9.16 is near median its 10-year median of 8.84. Over the past 10 years, this metric has ranged from a low of 2.43 to a high of 20.14. The Medical Devices & Instruments industry median PS Ratio is 2.91. Poly Medicure's value of 9.16 is 214.8% above this industry median. Based on the distribution chart, Poly Medicure ranks #666 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Poly Medicure has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Poly Medicure's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Poly Medicure ranks #666 out of 803 companies for PS Ratio. This places Poly Medicure in the lower half of its industry. The industry median PS Ratio is 2.91. Poly Medicure's value of 9.16 is 214.8% above this benchmark. Historically, Poly Medicure's own PS Ratio has ranged from 2.43 to 20.14 over the past decade. While the company's 10-year median is 8.84 vs. the industry median of 2.91, Poly Medicure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.91, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poly Medicure's current PS Ratio of 9.16 is 214.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Poly Medicure and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poly Medicure's current PS Ratio is 9.16, which is near median its own 10-year median of 8.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poly Medicure stock overvalued right now?
Based on GuruFocus' analysis, Poly Medicure (NSE:POLYMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,368.71, compared to a current price of ₹1,702.00 — trading 28.1% below its estimated fair value. The current PS Ratio is 9.16, which is near median its 10-year median of 8.84 and 214.8% above the Medical Devices & Instruments industry median of 2.91. Poly Medicure's overall GF Score™ is 99/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Poly Medicure (NSE:POLYMED), the current PS Ratio is 9.16 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poly Medicure (NSE:POLYMED) Overvalued in 2026?
Based on GuruFocus' analysis, Poly Medicure stock appears to be undervalued.
The current stock price of ₹1,702.00 is trading 28.1% below its estimated GF Value™ of ₹2,368.71.
GuruFocus considers Poly Medicure to be Modestly Undervalued.
Key valuation signals for NSE:POLYMED:
PS Ratio: 9.16 (near median its 10-year median of 8.84)
GF Value™: ₹2,368.71 vs. price of ₹1,702.00 (28.1% below fair value)
Industry Position: 214.8% above the Medical Devices & Instruments median (#666 of 803)
No single metric tells the full story. See the NSE:POLYMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
99GF Score
Get the complete analysis for NSE:POLYMED
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:POLYMED has been successfully added to your 
